BRIUMVI (ublituximab-xiiy) — NDA/BLA submission
H2 2026
We look forward to engaging with regulatory authorities regarding these data, with the goal of submitting a supplemental BLA in the second half of 2026.Source filing
TGTX biotech catalysts & pipeline
TG THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
subcutaneous BRIUMVI (ublituximab) — Topline data
Sep 2026–Mar 2027
Announce topline Phase 3 data for subcutaneous BRIUMVI year-end 2026/first quarter 2027Source filing